CHURCHILL MANAGEMENT Corp Invests $445,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

CHURCHILL MANAGEMENT Corp purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 18,392 shares of the company’s stock, valued at approximately $445,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Commonwealth Equity Services LLC bought a new stake in Hims & Hers Health in the second quarter valued at approximately $479,000. Victory Capital Management Inc. increased its position in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after buying an additional 1,212 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in Hims & Hers Health during the 2nd quarter worth $1,918,000. DekaBank Deutsche Girozentrale bought a new position in Hims & Hers Health during the second quarter worth about $143,000. Finally, WINTON GROUP Ltd bought a new position in Hims & Hers Health during the second quarter worth about $332,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Citigroup lowered shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $27.91 on Friday. The stock has a 50 day moving average price of $27.51 and a 200 day moving average price of $21.76. The stock has a market capitalization of $6.10 billion, a PE ratio of 63.44 and a beta of 1.31. Hims & Hers Health, Inc. has a 52 week low of $8.14 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.04) EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In related news, insider Michael Chi sold 7,259 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the sale, the insider now owns 193,601 shares in the company, valued at approximately $4,659,976.07. This represents a 3.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,080,208 shares of company stock valued at $29,106,823 in the last quarter. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.